NCT05188859View on ClinicalTrials.gov

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Mesothelioma, MalignantMesothelioma, Malignant PleuralMesothelioma Malignant Advanced
Interventions
DRUG

Sintilimab+Anlotinib+Pemetrexed+Cisplatin

Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2

Trial Locations (2)

Unknown

RECRUITING

Shanxi Provincial Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER